

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 58256

Manuscript Type: SYSTEMATIC REVIEWS

Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and meta-analysis

Yu-Qiong Xu, Xiang Long, Ming Han, Ming-Qiang Huang, Jia-Fa Lu, Xue-Dong Sun, Wei Han

Abstract

BACKGROUND

Lung cancer is a major cause of death among patients, and non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers in many countries.

AIM

To evaluate the clinical benefit (CB) of COX-2 inhibitors in patients with advanced NSCLC using systematic review.

METHODS

We searched the six electronic databases up until December 9, 2019, for studies that

Match Overview

1	Internet 71 words crawled on 12-Jun-2015 www.uspreventiveservicestaskforce.org	2%
2	Internet 36 words crawled on 28-Oct-2020 journals.plos.org	1%
3	Internet 33 words crawled on 18-Sep-2020 www.cochranelibrary.com	1%
4	Internet 33 words crawled on 30-Apr-2015 www.nhmrc.gov.au	1%
5	Internet 27 words crawled on 17-Oct-2020 doaj.org	1%
6	Internet 24 words crawled on 15-Jul-2020 systematicreviewsjournal.biomedcentral.com	1%
7	Internet 21 words crawled on 14-Apr-2018 www.annsaudimed.net	<1%
8	Internet 18 words crawled on 07-Oct-2015	<1%



ALL

IMAGES

VIDEOS

55,600 Results

Any time ▼

Clinical Profile of Cyclooxygenase-2 Inhibitors in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805232>

Results: Nine randomized clinical trials, comprising 1679 patients with NSCLC, were included in the final meta-analysis. The pooled ORR of patients who have NSCLC with COX-2 inhibitors was significantly higher than that without COX-2 inhibitors.

Cited by: 12

Author: Yuan Yuan Zhou, Zhi Gang Hu, Fan Jun Z...

Publish Year: 2016

Pooled analysis of the clinical benefit of cyclooxygenase ...

<https://tcr.amegroups.com/article/view/30176/html> ▼

Background: The purpose of this study was to perform a systematic review of the interventions for advanced non-small cell lung cancer (NSCLC) including chemotherapy alone and chemotherapy plus COX-2 inhibitors to identify and discuss the cause of any variation across studies and to explore the best currently available evidence. Methods: The literature was comprehensively searched to identify ...

Author: Wei Zheng, Zhi-Min Liao, Yan Fu, Ya...

Publish Year: 2019

Cyclooxygenase-2 inhibitors for non-small-cell lung cancer ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106666>

Several preclinical and clinical studies have demonstrated that cyclooxygenase-2 (COX-2) inhibitors are efficient for the treatment of non-small-cell lung cancer (NSCLC). However, two recent phase III clinical trials using COX-2 inhibitors in combination with platinum-based chemotherapy failed to demonstrate a survival benefit.

Cited by: 8

Author: Hiroshi Yokouchi, Kenya Kanazawa, Taka...

Publish Year: 2014

Clinical Profile of Cyclooxygenase-2 Inhibitors in ...

<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0151939> ▼

Mar 23, 2016 · Background Evidence on the benefits of combining cyclooxygenase-2 inhibitor (COX-2) in treating non-small cell lung cancer (NSCLC) is still controversial. We investigated the efficacy and safety profile of cyclooxygenase-2 inhibitors in treating NSCLC. Methods The first meta-analysis of eligible studies was performed to assess the effect of COX-2 inhibitors for patients with NSCLC on ...

Cited by: 12

Author: Yuan Yuan Zhou, Zhi Gang Hu, Fan Jun Z...

Publish Year: 2016

Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of



ALL

IMAGES

VIDEOS

157,000 Results

Any time ▾

[Clinical benefits of adjuvant chemotherapy with ...](#)

<https://wjso.biomedcentral.com/articles/10.1186/s12957-020-02041-0> ▾

Oct 08, 2020 · In cases of **non-small cell lung cancer** (NSCLC), surgery remains the best option for cure, but surgery is of **benefit** only when the disease is localized. Although **adjuvant chemotherapy** reportedly has a significant beneficial effect on survival, the **benefit** of a carboplatin (CBDCA) regimen is unclear. We therefore investigated the efficacy and tolerability of CBDCA (area under the curve 5) plus ...

Author: Shinogu Takashima, Kazuhiro Imai, Mai... **Publish Year:** 2020

[Clinical Profile of Cyclooxygenase-2 Inhibitors in ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805232>

Lung cancer is a major cause of death among patients, and **non-small cell lung cancer** (NSCLC) accounts for more than 80% of all **lung cancers** over many countries. The average survival time is 6–10 months for patients with **advanced** NSCLC in performance status 0–2 receiving palliative first-line **chemotherapy** [1 – 4].

Cited by: 13

Author: Yuan Yuan Zhou, Zhi Gang Hu, Fan Jun Zen...

Publish Year: 2016

[Adjuvant Chemotherapy for Resected Non–Small-Cell Lung Cancer](#)

<https://www.cancernetwork.com/view/adjuvant...> ▾

Nov 01, 2005 · **Non-Small Cell Lung Cancer** Collaborative Group. **Chemotherapy in non-small cell lung cancer: A meta-analysis** using updated data on individual patients from 52 randomised **clinical trials**. *BMJ* 311:899-909, 1995. 17. Holmes EC, Gail M: Surgical **adjuvant** therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma.

[Role of Adjuvant Chemotherapy in Patients With Resected ...](#)

<https://ascopubs.org/doi/10.1200/JCO.2004.01.153>

Sep 21, 2016 · Purpose The role of **adjuvant chemotherapy** in patients with resected **non–small-cell lung cancer** (NSCLC) remains to be defined. This study was aimed at re-evaluating the effectiveness of **adjuvant chemotherapy** in patients with resected NSCLC, by performing a **meta-analysis** of relevant trials. Methods We performed a literature search to identify trials reported after the publication of a ...

Cited by: 260

Author: Katsuyuki Hotta, Keitaro Matsuo, Hiroshi U...

Publish Year: 2004

[Predictors of Outcomes in Patients with EGFR-Mutated Non ...](#)

[ALL](#)
[IMAGES](#)
[VIDEOS](#)
[MAPS](#)
[NEWS](#)
[SHOPPING](#)

197,000 Results Any time ▾

Clinical benefits of adjuvant chemotherapy with ...

<https://wjso.biomedcentral.com/articles/10.1186/s12957-020-02041-0> ▾

Oct 08, 2020 · In cases of **non-small cell lung cancer** (NSCLC), surgery remains the best option for cure, but surgery is of **benefit** only when the disease is localized. Although **adjuvant chemotherapy** reportedly has a significant beneficial effect on survival, the **benefit** of a carboplatin (CBDCA) regimen is unclear. We therefore investigated the efficacy and tolerability of CBDCA (area under the curve 5) plus ...

Author: Shinogu Takashima, Kazuhiro Imai, M... **Publish Year:** 2020

Pooled analysis of the clinical benefit of cyclooxygenase ...

<https://tcr.amegroups.com/article/view/30176/html> ▾

Background: The purpose of this study was to perform a **systematic review** of the interventions for **advanced non-small cell lung cancer** (NSCLC) including **chemotherapy** alone and **chemotherapy** plus **COX-2 inhibitors** to identify and discuss the cause of any variation across studies and to explore the best currently available evidence. Methods: The literature was comprehensively searched to identify ...

Author: Wei Zheng, Zhi-Min Liao, Yan Fu, Ya-... **Publish Year:** 2019

Clinical Profile of Cyclooxygenase-2 Inhibitors in ...

<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0151939> ▾

Mar 23, 2016 · Background Evidence on the benefits of combining cyclooxygenase-2 inhibitor (**COX-2**) in treating **non-small cell lung cancer** (NSCLC) is still controversial. We investigated the efficacy and safety profile of cyclooxygenase-2 **inhibitors** in treating NSCLC. Methods The first **meta-analysis** of eligible studies was performed to assess the effect of **COX-2 inhibitors** for patients with NSCLC on ...

Cited by: 13 **Author:** Yuan Yuan Zhou, Zhi Gang Hu, Fan Jun ...

Publish Year: 2016

Clinical Profile of Cyclooxygenase-2 Inhibitors in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805232>

Lung cancer is a major cause of death among patients, and **non-small cell lung cancer** (NSCLC) accounts for more than 80% of all **lung** cancers over many countries. The average survival time is 6–10 months for patients with **advanced** NSCLC in performance status 0–2 receiving palliative first-line **chemotherapy** [1 – 4].